Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
University of Chicago, Chicago, Ill;
Fox Chase Cancer Center, Philadelphia, Pa
Objective: To determine mutations of the receptor tyrosine kinase c-MET in head and neck squamous cell carcinoma (HNSCC) and evaluate c-MET as a potential novel target using c-MET inhibitor SU11274.
Design: A total of 128 HNSCC, dysplastic, and normal tissues (using immunohistochemistry) and 7 HNSCC cell lines (using immunoblot) were evaluated for c-MET, phospho-c-MET, and hepatocyte growth factor.
Seiwert TY, Klein-Szanto AJ, Jagadeeswaran R, Tretiakova M, Martin L, Lingen MW, Cohen EE, Ridge JA, Vokes EE, Salgia R. S115 The Receptor Tyrosine Kinase c-MET Is Mutated in Head and Neck Cancer and Is a Promising Novel Target. Arch Otolaryngol Head Neck Surg. 2006;132(8):864. doi:10.1001/archotol.132.8.864-b